ArticleCureus2025
Cefmetazole-Induced Coagulopathy in a Patient With Vitamin K Deficiency: A Case Report With Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefmetazole (CMZ), a cephamycin antibiotic containing an N-methyltetrazolethiol (NMTT) group, is known to interfere with vitamin K metabolism, potentially causing coagulation disorders. We present the case of a 78-year-old man with chronic kidney disease who developed a coagulation disorder during CMZ administration, exacerbated by chronic vitamin K deficiency from prolonged enteral nutrition. In the context of chronic vitamin K deficiency precipitated by prolonged enteral nutrition for renal disease, the administration of CMZ-a medication that disrupts vitamin K metabolism and reduces coagulation factor activity through a mechanism similar to that of warfarin-led to abnormal blood coagulation test results. Clinical improvement followed the discontinuation of CMZ and vitamin K supplementation. This report highlights the importance of monitoring vitamin K status in patients receiving CMZ, particularly those with risk factors for deficiency, and reviews the relevant literature to highlight the mechanisms and management strategies for such complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.